#USA #Orlando #Myeloproliferative Neoplasms #Polycythemia Vera #MPN Research Foundation

MPN Research Foundation Showcases Key Research at ASH 2025

The MPN Research Foundation, a pivotal organization in the field of myeloproliferative neoplasms (MPNs), will present two significant abstracts during the upcoming 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 6-9, 2025, in Orlando, Florida. This event provides a prestigious platform for discussing advances in hematology, making it an ideal venue for sharing groundbreaking research focused on patient experiences and treatment advancement in MPNs.

Kapila Viges, CEO of the MPN Research Foundation, emphasized the organization's mission: "As a patient-centered research organization focused on understanding the causes of myeloproliferative neoplasms, our primary goal is to promote original research in pursuit of new treatments — and ultimately a cure — for MPNs." This statement reflects a commitment to not only advancing scientific knowledge but also ensuring that the voices of those affected by MPNs—patients and caregivers alike—integrate seamlessly into future research and advocacy efforts.

Oral Presentation Highlights

One of the key presentations, titled "Global Assessment of Patient and Caregiver Unmet Needs in Myeloproliferative Neoplasms," will be provided by Sara Douglas, Director of Patient Engagement at the MPN Research Foundation. Scheduled for December 8th from 4:00 PM to 4:15 PM EST, this presentation aims to shed light on the critical unmet needs faced by patients diagnosed with MPNs. Despite recent advancements in treatment options, many patients continue to experience gaps in support, particularly relating to clinical trial awareness, symptom management, and care that aligns with their individual treatment goals.

In this 2024 assessment, insights were collected from a variety of stakeholders within the MPN community, identifying essential areas such as patient education, symptom management, access to specialized healthcare, and an overall awareness of clinical trials.

Poster Session Insights

The second abstract will be featured during a poster session, scheduled for December 6, from 5:30 PM to 7:30 PM EST. This poster will detail findings derived from surveys conducted by both the MPN Research Foundation and Haymarket Medical Education, examining the views of patients and healthcare professionals regarding the diagnosis and management of polycythemia vera (PV). This chronic blood cancer, characterized by an abnormal increase in red blood cells, presents a unique set of challenges and burdens for both patients and their providers, making this research crucial for improving patient care.

The collaborative effort aims to highlight gaps in understanding from both patient and clinician perspectives to foster better treatment methodologies and create more impactful patient-centered care pathways. By delving into patient experiences and expectations, this research provides invaluable insights into treatment goals and the decision-making processes in the management of PV.

About the MPN Research Foundation

Established in 1999, the MPN Research Foundation has emerged as the first dedicated organization in the MPN field, focusing on funding and promoting original research targeting novel treatments and potential cures for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). With a steadfast commitment to advancing research, the foundation continues to play a significant role in defining the future landscape of MPN treatments.

For more information on the ongoing research and initiatives of the MPN Research Foundation, visit their official website at mpnresearchfoundation.org. This ASH 2025 event serves not just as an academic gathering but as a critical juncture for stakeholders in the MPN community to connect, share knowledge, and advance the overall understanding of these complex diseases.